| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
The 
- and 
-chains of the TCR from a highly avid anti-gp100 CTL clone were isolated and used to construct retroviral vectors that can mediate high efficiency gene transfer into primary human lymphocytes. Expression of this TCR gene was confirmed by Western blot analysis, immunocytometric analysis, and HLA Ag tetramer staining. Gene transfer efficiencies of >50% into primary lymphocytes were obtained without selection for transduced cells using a method of prebinding retroviral vectors to cell culture vessels before the addition of lymphocytes. The biological activity of transduced cells was confirmed by cytokine production following coculture with stimulator cells pulsed with gp100 peptides, but not with unrelated peptides. The ability of this anti-gp100 TCR gene to transfer high avidity Ag recognition to engineered lymphocytes was confirmed in comparison with highly avid antimelanoma lymphocytes by the high levels of cytokine production (>200,000 pg/ml IFN-
), by recognition of low levels of peptide (<200 pM), and by HLA class I-restricted recognition and lysis of melanoma tumor cell lines. CD4+ T cells engineered with this anti-gp100 TCR gene were Ag reactive, suggesting CD8-independent activity of the expressed TCR. Finally, nonmelanoma-reactive tumor-infiltrating lymphocyte cultures developed antimelanoma activity following anti-gp100 TCR gene transfer. In addition, tumor-infiltrating lymphocytes with reactivity against non-gp100 melanoma Ags acquired gp100 reactivity and did not lose the recognition of autologous melanoma Ags following gp100 TCR gene transfer. These results suggest that lymphocytes genetically engineered to express anti-gp100 TCR may be of value in the adoptive immunotherapy of patients with melanoma.
This article has been cited by other articles:
|
|
 |
|
  A. Kruschinski, A. Moosmann, I. Poschke, H. Norell, M. Chmielewski, B. Seliger, R. Kiessling, T. Blankenstein, H. Abken, and J. Charo Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas PNAS, November 11, 2008; 105(45): 17481 - 17486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. de Witte, A. Jorritsma, A. Kaiser, M. D. van den Boom, M. Dokter, G. M. Bendle, J. B. A. G. Haanen, and T. N. M. Schumacher Requirements for Effective Antitumor Responses of TCR Transduced T Cells J. Immunol., October 1, 2008; 181(7): 5128 - 5136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Rosenberg Overcoming obstacles to the effective immunotherapy of human cancer PNAS, September 2, 2008; 105(35): 12643 - 12644. [Full Text] [PDF]
|
|
|
|
|
|
A. Chhabra, L. Yang, P. Wang, B. Comin-Anduix, R. Das, N. G. Chakraborty, S. Ray, S. Mehrotra, H. Yang, C. L. Hardee, et al. CD4+CD25- T Cells Transduced to Express MHC Class I-Restricted Epitope-Specific TCR Synthesize Th1 Cytokines and Exhibit MHC Class I-Restricted Cytolytic Effector Function in a Human Melanoma Model J. Immunol., July 15, 2008; 181(2): 1063 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Conrad, K. Gebhard, H. Kronig, J. Neudorfer, D. H. Busch, C. Peschel, and H. Bernhard CTLs Directed against HER2 Specifically Cross-React with HER3 and HER4 J. Immunol., June 15, 2008; 180(12): 8135 - 8145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Kieback, J. Charo, D. Sommermeyer, T. Blankenstein, and W. Uckert A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer PNAS, January 15, 2008; 105(2): 623 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Santomasso, W. K. Roberts, A. Thomas, T. Williams, N. E. Blachere, M. E. Dudley, A. N. Houghton, J. B. Posner, and R. B. Darnell A T cell receptor associated with naturally occurring human tumor immunity PNAS, November 27, 2007; 104(48): 19073 - 19078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jorritsma, R. Gomez-Eerland, M. Dokter, W. van de Kasteele, Y. M. Zoet, I. I. N. Doxiadis, N. Rufer, P. Romero, R. A. Morgan, T. N. M. Schumacher, et al. Selecting highly affine and well-expressed TCRs for gene therapy of melanoma Blood, November 15, 2007; 110(10): 3564 - 3572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Thomas, S.-A. Xue, M. Cesco-Gaspere, E. San Jose, D. P. Hart, V. Wong, R. Debets, B. Alarcon, E. Morris, and H. J. Stauss Targeting the Wilms Tumor Antigen 1 by TCR Gene Transfer: TCR Variants Improve Tetramer Binding but Not the Function of Gene Modified Human T Cells J. Immunol., November 1, 2007; 179(9): 5803 - 5810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhao, A. D. Bennett, Z. Zheng, Q. J. Wang, P. F. Robbins, L. Y. L. Yu, Y. Li, P. E. Molloy, S. M. Dunn, B. K. Jakobsen, et al. High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines J. Immunol., November 1, 2007; 179(9): 5845 - 5854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W Yang, E. Beaudoin, L Lu, R. Du Pasquier, M. Kuroda, R. Willemsen, I. Koralnik, and R. Junghans Chimeric immune receptors (CIRs) specific to JC virus for immunotherapy in progressive multifocal leukoencephalopathy (PML) Int. Immunol., September 1, 2007; 19(9): 1083 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhao, M. R. Parkhurst, Z. Zheng, C. J. Cohen, J. P. Riley, L. Gattinoni, N. P. Restifo, S. A. Rosenberg, and R. A. Morgan Extrathymic Generation of Tumor-Specific T Cells from Genetically Engineered Human Hematopoietic Stem Cells via Notch Signaling Cancer Res., March 15, 2007; 67(6): 2425 - 2429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kuball, M. L. Dossett, M. Wolfl, W. Y. Ho, R.-H. Voss, C. Fowler, and P. D. Greenberg Facilitating matched pairing and expression of TCR chains introduced into human T cells Blood, March 15, 2007; 109(6): 2331 - 2338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Johnson, B. Heemskerk, D. J. Powell Jr., C. J. Cohen, R. A. Morgan, M. E. Dudley, P. F. Robbins, and S. A. Rosenberg Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes J. Immunol., November 1, 2006; 177(9): 6548 - 6559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Morgan, M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes Science, October 6, 2006; 314(5796): 126 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Cohen, Y. Zhao, Z. Zheng, S. A. Rosenberg, and R. A. Morgan Enhanced Antitumor Activity of Murine-Human Hybrid T-Cell Receptor (TCR) in Human Lymphocytes Is Associated with Improved Pairing and TCR/CD3 Stability. Cancer Res., September 1, 2006; 66(17): 8878 - 8886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. W. H. G. Kessels, K. Schepers, M. D. van den Boom, D. J. Topham, and T. N. M. Schumacher Generation of T Cell Help through a MHC Class I-Restricted TCR J. Immunol., July 15, 2006; 177(2): 976 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Cohen, Z. Zheng, R. Bray, Y. Zhao, L. A. Sherman, S. A. Rosenberg, and R. A. Morgan Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR J. Immunol., November 1, 2005; 175(9): 5799 - 5808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-A. Xue, L. Gao, D. Hart, R. Gillmore, W. Qasim, A. Thrasher, J. Apperley, B. Engels, W. Uckert, E. Morris, et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells Blood, November 1, 2005; 106(9): 3062 - 3067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tsuji, M. Yasukawa, J. Matsuzaki, T. Ohkuri, K. Chamoto, D. Wakita, T. Azuma, H. Niiya, H. Miyoshi, K. Kuzushima, et al. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes Blood, July 15, 2005; 106(2): 470 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Alajez, J. Schmielau, M. D. Alter, M. Cascio, and O. J. Finn Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution Blood, June 15, 2005; 105(12): 4583 - 4589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. Morris, A. Tsallios, G. M. Bendle, S.-a. Xue, and H. J. Stauss A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection PNAS, May 31, 2005; 102(22): 7934 - 7939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhao, Z. Zheng, P. F. Robbins, H. T. Khong, S. A. Rosenberg, and R. A. Morgan Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines J. Immunol., April 1, 2005; 174(7): 4415 - 4423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Charo, S. E. Finkelstein, N. Grewal, N. P. Restifo, P. F. Robbins, and S. A. Rosenberg Bcl-2 Overexpression Enhances Tumor-Specific T-Cell Survival Cancer Res., March 1, 2005; 65(5): 2001 - 2008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Roszkowski, G. E. Lyons, W. M. Kast, C. Yee, K. Van Besien, and M. I. Nishimura Simultaneous Generation of CD8+ and CD4+ Melanoma-Reactive T Cells by Retroviral-Mediated Transfer of a Single T-Cell Receptor Cancer Res., February 15, 2005; 65(4): 1570 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Palmer, S. Balasubramaniam, K.-i. Hanada, C. Wrzesinski, Z. Yu, S. Farid, M. R. Theoret, L. N. Hwang, C. A. Klebanoff, L. Gattinoni, et al. Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction J. Immunol., December 15, 2004; 173(12): 7209 - 7216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nakatsura, H. Komori, T. Kubo, Y. Yoshitake, S. Senju, T. Katagiri, Y. Furukawa, M. Ogawa, Y. Nakamura, and Y. Nishimura Mouse Homologue of a Novel Human Oncofetal Antigen, Glypican-3, Evokes T-Cell-Mediated Tumor Rejection without Autoimmune Reactions in Mice Clin. Cancer Res., December 15, 2004; 10(24): 8630 - 8640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Rosenberg and M. E. Dudley Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes PNAS, October 5, 2004; 101(suppl_2): 14639 - 14645. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
